Contributions
Abstract: EP1621
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Background: Immunomodulatory treatments are indicated as first line therapy in MS patients after the first demyelinating event. Correlation of MR activity in such patients especially enhanced lesions and response to 1st line therapies is not known.
Objectives: To evaluate correlation of MR activity and response to first line therapies in MS patients.
Material and methods: Based on EDMUS data bank, we retrospectively included MS patients treated by a first line treatment followed during 2 years. Criteria analysis were annual rate of relapses (ARR) and EDSS score at year 1 and 2, compared between patients without (Gd- ) and with (Gd+) activity at the baseline MR examination. Extensive follow at 5 years was available in a part of the patients.
Results: From 2180 MS patients included in our MS base (EDMUS), 149 MS had inclusion criteria: 91 Gd- and 58 Gd + . Group Gd - characteristics were: sex ratio (M 19 / F 72), mean age of onset: 32.3, mean follow-up : 72 months. Mean EDSS score at the beginning of therapy was 0.7. Most of them (94 %) had an EDSS score below 2. Mean duration of first line therapy was 39. 6 months. Gd+ group consisted of 58 patients (M12 / F 46), mean age of onset 31.3 yo, mean follow-up: 60 months, mean EDSS score at the prescription : 0.9 (91 % < 2), duration of treatment: 32.1 months.
At year 1, ARR was 0.35 in Gd - and 0.49 in Gd + group, mean EDSS score 0.7 and 0.87 (not statistically significant) . At year 2, ARR was 0.25 in Gd - and 0.35 in Gd + patients, mean EDSS score 0.7 and 1.06 (NS). At year 5, EDSS score was available for 54 patients of Gd - group and 29 from Gd +. It was respectively 0.6 and 1.6 (p < 0.05).
Conclusions: Occurrence of enhanced lesions on MR at the onset of the first line therapy, suggests a more severe evolution. ARR and mean EDSS score is slightly more important at year 1 and 2 in Gd + patients. Long term EDSS score is worst in Gd + patients treated by first line therapy. These results could suggest to treat some MS patients with GD + lesions directly by a 2nd line therapy.
Disclosure:
Pierre Labauge: nothing to disclose
Xavier Ayrignac: nothing to disclose
Nicolas Collongues: received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi- Genzyme, Roche and Teva;
Laurent Kremer: nothing to disclose
Sephane Kremer: nothing to disclose
Jean-Claude Ongagna: nothing to disclose
Lucas Corti: nothing to disclose
Clarisse Carra Dalliere: nothing to disclose
Frederic Pinna: nothing to disclose
Cedric Theis: nothing to disclose
Jérome de Sèze: nothing to disclose
Abstract: EP1621
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Background: Immunomodulatory treatments are indicated as first line therapy in MS patients after the first demyelinating event. Correlation of MR activity in such patients especially enhanced lesions and response to 1st line therapies is not known.
Objectives: To evaluate correlation of MR activity and response to first line therapies in MS patients.
Material and methods: Based on EDMUS data bank, we retrospectively included MS patients treated by a first line treatment followed during 2 years. Criteria analysis were annual rate of relapses (ARR) and EDSS score at year 1 and 2, compared between patients without (Gd- ) and with (Gd+) activity at the baseline MR examination. Extensive follow at 5 years was available in a part of the patients.
Results: From 2180 MS patients included in our MS base (EDMUS), 149 MS had inclusion criteria: 91 Gd- and 58 Gd + . Group Gd - characteristics were: sex ratio (M 19 / F 72), mean age of onset: 32.3, mean follow-up : 72 months. Mean EDSS score at the beginning of therapy was 0.7. Most of them (94 %) had an EDSS score below 2. Mean duration of first line therapy was 39. 6 months. Gd+ group consisted of 58 patients (M12 / F 46), mean age of onset 31.3 yo, mean follow-up: 60 months, mean EDSS score at the prescription : 0.9 (91 % < 2), duration of treatment: 32.1 months.
At year 1, ARR was 0.35 in Gd - and 0.49 in Gd + group, mean EDSS score 0.7 and 0.87 (not statistically significant) . At year 2, ARR was 0.25 in Gd - and 0.35 in Gd + patients, mean EDSS score 0.7 and 1.06 (NS). At year 5, EDSS score was available for 54 patients of Gd - group and 29 from Gd +. It was respectively 0.6 and 1.6 (p < 0.05).
Conclusions: Occurrence of enhanced lesions on MR at the onset of the first line therapy, suggests a more severe evolution. ARR and mean EDSS score is slightly more important at year 1 and 2 in Gd + patients. Long term EDSS score is worst in Gd + patients treated by first line therapy. These results could suggest to treat some MS patients with GD + lesions directly by a 2nd line therapy.
Disclosure:
Pierre Labauge: nothing to disclose
Xavier Ayrignac: nothing to disclose
Nicolas Collongues: received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi- Genzyme, Roche and Teva;
Laurent Kremer: nothing to disclose
Sephane Kremer: nothing to disclose
Jean-Claude Ongagna: nothing to disclose
Lucas Corti: nothing to disclose
Clarisse Carra Dalliere: nothing to disclose
Frederic Pinna: nothing to disclose
Cedric Theis: nothing to disclose
Jérome de Sèze: nothing to disclose